Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 40 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Standard Trivalent Influenza Vaccine Clear all

Conditions: Influenza, Healthy Volunteers
Interventions: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1, TIV mRNA-neuraminidase (NA), TIV mRNA-HA Vaccine 2, Quadrivalent Influenza Standard Dose Vaccine, Quadrivalent Influenza Vaccine High Dose; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 50 Years and older
Enrollment: 1,162 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 21
States / cities: Birmingham, Alabama • Mobile, Alabama • Tempe, Arizona + 18 more

Conditions: Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions: Split, Inactivated, Trivalent Influenza Vaccine; Biological
Lead sponsor: Sanofi; Industry
Eligibility: 65 Years and older
Enrollment: 817 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2008
U.S. locations: 17
States / cities: Alabaster, Alabama • Tucson, Arizona • Fountain Valley, California + 14 more

Conditions: Influenza
Interventions: Fluzone®; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lymphoma
Interventions: Trivalent Baculovirus-expressed Influenza HA vaccine; Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza
Interventions: Fluzone® (IM), Fluzone®; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 217 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Influenza Vaccines, Aged
Interventions: MAS-1 adjuvant and influenza HA antigen, standard dose, inactivated trivalent influenza vaccine (TIV); Biological
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 65 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Palo Alto, California • Iowa City, Iowa • Minneapolis, Minnesota + 1 more

Conditions: Influenza
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 65 Years to 99 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Influenza, Myxovirus Infection
Interventions: Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1), Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2), Split, Inactivated, Trivalent Influenza Vaccine (Standard dose), Split, Inactivated, Trivalent Influenza Vaccine (High-dose); Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 2,098 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 29
States / cities: Alabaster, Alabama • Mobile, Alabama • Chandler, Arizona + 26 more

Conditions: Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer
Interventions: Fluzone Trivalent; Biological
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Adult Stem Cell Hematopoetic Transplant
Interventions: High-Dose Trivalent Inactivated Influenza Vaccine (HD-TIV), Standard Dose Trivalent Inactivated Flu Vaccine; Biological
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Inflammatory Bowel Diseases
Interventions: Pneumococcal Pneumonia vaccine, Influenza vaccine, Hepatitis B vaccine; Biological
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Orthomyxoviridae Infection, Influenza, Myxovirus Infection
Interventions: Influenza Virus Vaccine USP Trivalent Types A and B; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 4,292 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 46
States / cities: Hoover, Alabama • Huntsville, Alabama • Mobile, Alabama + 40 more

Conditions: Cancer, Influenza Viral Infections
Interventions: Standard Trivalent Influenza Vaccine, High-Dose Influenza Vaccine; Biological
Lead sponsor: Saad Jamshed MD; Other
Eligibility: 18 Years to 64 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 2
States / cities: Rochester, New York

Conditions: Hematopoietic Cell Transplantation Recipient, Malignant Neoplasm, Influenza
Interventions: Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Laboratory Biomarker Analysis; Biological · Other
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 3 Years to 17 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 9
States / cities: San Francisco, California • Kansas City, Missouri • Cincinnati, Ohio + 6 more

Conditions: Immunizations, Vaccination, Influenza, School Health
Interventions: School based flu vaccine: Low intensity, School based flu vaccine: High intensity; Behavioral
Lead sponsor: Monroe County Department of Public Health; Other
Eligibility: 4 Years to 13 Years
Enrollment: 25,366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Influenza, Orthomyxoviruses, Myxovirus Infection
Interventions: Influenza virus vaccine - cell-based (2007-2008 Formulation), Influenza virus vaccine (2007-2008 Formulation); Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 729 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 15
States / cities: Hoover, Alabama • Mobile, Alabama • Tucson, Arizona + 12 more

Conditions: Heart Failure, Myocardial Infarction
Interventions: High Dose Trivalent Influenza Vaccine, Standard Dose Quadrivalent Influenza Vaccine; Biological
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 5,388 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 127
States / cities: Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 93 more

Conditions: Healthy Adult Participants, Age 65 and Older, Age 18 to 40, Immunology
Interventions: Trivalent inactivated influenza vaccine, RabAvert; Biological
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: HIV, Cancer
Interventions: Fluzone High Dose Vaccine, Fluzone Standard Dose Vaccine; Biological
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 3 Years to 21 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Seasonal Influenza
Interventions: mRNA-1010, Fluarix Trivalent; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 9 Years to 17 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Modesto, California • Aurora, Colorado • Minneapolis, Minnesota + 3 more

Conditions: Influenza, Human, Transplantation Infection
Interventions: influenza trivalent inactive vaccine, influenza trivalent inactive vaccine high dose; Biological
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years to 70 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: Influenza
Interventions: HD Vaccine, SD Vaccine, Free Vaccine, Usual Care; Biological
Lead sponsor: Insight Therapeutics, LLC; Other
Eligibility: 65 Years and older
Enrollment: 823 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 3
States / cities: Cleveland, Ohio • Providence, Rhode Island • Norfolk, Virginia

Conditions: Influenza
Interventions: Trivalent inactivated influenza vaccine, Trivalent Baculovirus-expressed Influenza HA vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2010
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Influenza
Interventions: High-Dose trivalent influenza vaccine (Split virion, Inactivated), Standard-dose trivalent influenza vaccine (Split virion, Inactivated); Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 50 Years to 64 Years
Enrollment: 1,180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 20
States / cities: Los Alamitos, California • Fort Myers, Florida • Hollywood, Florida + 16 more

Search by objective public record fields.

A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older

Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects

Young Adult Influenza Vaccine Immunogenicity Substudy

Influenza Vaccination in Patients Receiving Antineoplastic Therapy for Non-Hodgkin's Lymphoma

Immunogenicity and Safety of Different Doses of Fluzone® Influenza

MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly

Elderly Influenza Vaccine Immunogenicity Substudy

Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects

A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision

Standard vs High-Dose Trivalent Inactivated Flu Vaccine in Adult Hematopoetic Stem Cell Transplant (HSCT) Recipients

Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab

Study of Fluzone Vaccine Administered by Intradermal Route in Comparison With Standard Fluzone® in Adults

Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy

High Dose Flu Vaccine in Treating Children Who Have Undergone Donor Stem Cell Transplant

School Influenza Vaccine vs Standard of Care With Nested Trial of 2 Parent Notification Intensities

Immunogenicity of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine in Healthy Adult Subjects

INfluenza Vaccine to Effectively Stop Cardio Thoracic Events and Decompensated Heart Failure

Age-Associated Differences in Germinal Center Responses to Influenza and Rabies Vaccination in Humans

Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Children

Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.

High-Dose Influenza Vaccine in Nursing Homes

High Dose Influenza in Immunosuppressed Subjects

Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age